20 May 2016 11:43
Sinclair Pharma plc
Share Awards
London, 20 May 2016 Sinclair Pharma plc (SPH.L), ("Sinclair" or the "Company") the international aesthetics company, announces that the following Directors and the Company's Chief Financial Officer have today been allocated the following numbers of nil-cost options over ordinary shares in the Company ("Nil-Cost Options") following the first measurement date on 31 December 2015 under the terms of the Group's Value Creation Plan ("VCP"):
Name | Number of Nil-Cost Options | |
Chris Spooner, CEO | 1,912,528 | |
Christophe Foucher, COO | 1,195,330 | |
Alan Olby, CFO | 425,006 | |
A further 1,112,983 Nil-Cost Options have been granted to other senior employees of the Group.
50% of the Nil-Cost Options granted will become exercisable on the VCP's fifth measurement date with the remaining 50% of the Nil-Cost Options exercisable on the first anniversary of the fifth measurement date. The fifth measurement date will be 30 days after the preliminary announcement of the Company's results for the year ending 31 December 2019. No payment has been made for the grant of the Nil-Cost Options.
Additional details of the VCP scheme are set out in the Group's report and accounts to 30 June 2015 available on the Company's website (www.sinclairpharma.com).
Ends
For further information please contact:
Sinclair Pharma plc | Tel: +44 (0) 20 7467 6920 |
Chris Spooner Alan Olby |
Peel Hunt LLP (NOMAD and Broker) | Tel: +44 (0) 20 7418 8900 |
James Steel Oliver Jackson |
Media enquiries
FTI Consulting | Tel: +44 (0) 203 727 1000 |
Ben Atwell Brett Pollard
|
Notes to Editors:
About Sinclair Pharma plc
Sinclair Pharma plc is an international company operating in the fast growth, high gross margin, global aesthetics market. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies, which are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. The Company is planning entry to multiple new geographic markets and line extension launches over the next few years. Sinclair has an established sales and marketing presence in the leading EU markets and Brazil, and a network of international distributors. For more information, please visit www.sinclairpharma.com
"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward‐looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward‐looking statements due to a variety of factors.